These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

910 related articles for article (PubMed ID: 18070715)

  • 1. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of relapsed and relapsed refractory myeloma.
    Kastritis E; Mitsiades CS; Dimopoulos MA; Richardson PG
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide in the treatment of multiple myeloma.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide for the treatment of B-cell malignancies.
    Chanan-Khan AA; Cheson BD
    J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
    Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of plasma cell dyscrasias with lenalidomide.
    Dimopoulos MA; Kastritis E; Rajkumar SV
    Leukemia; 2008 Jul; 22(7):1343-53. PubMed ID: 18509355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in multiple myeloma.
    Sirohi B; Powles R
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1559-70. PubMed ID: 19895240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in oral therapy in the treatment of multiple myeloma.
    Doss DS
    Clin J Oncol Nurs; 2006 Aug; 10(4):514-20. PubMed ID: 16927905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
    Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.